These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 14998865)
1. Coronary ischemia related to alemtuzumab therapy. Basquiera AL; Berretta AR; García JJ; Palazzo ED Ann Oncol; 2004 Mar; 15(3):539-40. PubMed ID: 14998865 [No Abstract] [Full Text] [Related]
2. Alemtuzumab. Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950 [No Abstract] [Full Text] [Related]
3. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard? Goodman M J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616 [No Abstract] [Full Text] [Related]
4. Alemtuzumab for treatment of lymphoproliferative disorders. Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389 [No Abstract] [Full Text] [Related]
5. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Anoop P; Wotherspoon A; Matutes E Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308 [No Abstract] [Full Text] [Related]
6. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232 [TBL] [Abstract][Full Text] [Related]
13. A fatal case of alemtuzumab-associated interstitial pneumonitis. Creelan B; Ferber A Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357 [TBL] [Abstract][Full Text] [Related]
14. [Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics]. Doubek M; Jungová A; Brejcha M; Panovská A; Brychtová Y; Pospísil Z; Mayer J; Vnitr Lek; 2009 Jun; 55(6):549-54. PubMed ID: 19662885 [TBL] [Abstract][Full Text] [Related]
15. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413 [TBL] [Abstract][Full Text] [Related]
16. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923 [TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245 [No Abstract] [Full Text] [Related]
18. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Smolej L Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576 [No Abstract] [Full Text] [Related]